Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Thallion Pharmaceuticals and LFB Biotechnologies have recruited first patient in a randomized, double-blind, placebo-controlled Phase II Shigatec trial to investigate Shigamabs as a treatment for Shiga toxin-producing E. coli (STEC) infection.
Subscribe to our email newsletter
The high dose cohort (3 mg/kg/dose) Phase II trial expects to recruit around 21 patients in the trial.
The company anticipates to release the top line results of the trial before the end of current year.
Thallion CEO Allan Mandelzys said following the positive recommendation from the IDMC after the low dose cohort and the resumption of patient enrollment in their Shigatec trial, they continue to push forward with the clinical development of their novel Shigamabs treatment.
"Shigamabs represents the most advanced clinical treatment in development for the prevention of a condition in which the current standard of care is simply to hydrate, wait and then monitor disease progression," Mandelzys said.